ALK and anaplastic large cell lymphoma: About 20–30% of ALK-negative ALCL cases have a DUSP22-rearrangement (DUSP22-R), which has been reported to be associated with a favorable outcome [5-year overall survival (OS) of 80–90%] [7,44].